title: [Effect of pravastatine plus ezetimibe on carotid intima media thickness in patients with lupus erythematosus].
abstract: BACKGROUND
  Patients with systemic lupus erythematosus (SLE) have accelerated atherosclerosis that can be assessed by the carotid intima media thickness (CIMT) measurement. A prompt hypolipidemic treatment should be a part of the integral management. The aim of this study is to determine the effect of therapy with pravastatin plus ezetimibe on the CIMT in SLE patients.
  
  
  METHODS
  Longitudinal, prospective, quasi-experimental trial. Out of 60 SLE patients in whom a carotid ultrasound was performed, we chose 22 with a CIMT>0.7 mm who were administered pravastatin plus ezetimibe during 6 months with determination of CIMT at the end of the study. We performed the following tests: total cholesterol (TC), HDL-cholesterol, LDL-cholesterol, tryglicerides, C-reactive protein (CRP), liver function, muscle enzimes and glucose, basal and at the end of treatment.
  
  
  METHODS
  descriptive statistics and Wilcoxon test were used.
  
  
  RESULTS
  There were 22 women with an age of 42±6.3 years, average disease evolution 7.5±6.6 years, of whom, 18 concluded the study. Right basal CIMT was 0.829±0.1448 vs. final 0.688±0.1453, p<0.003; left CIMT was 0.820±0.1312 vs. 0.724±0.1348, p<0.004. TC 208 mg/dl vs 168 mg/dl, LDL-C 125 mg/dl vs. 72 mg/dl, p=0.0004. CRP 3.12 vs. 2.25 p=0.004. In 2 cases there were gastrointestinal, skin and muscle adverse effects.
  
  
  CONCLUSIONS
  Treatment with pravastatin plus ezetimibe decreases the CIMT with improvement in the concentration of total cholesterol, LDL-C and CRP levels with good toleration.
authors.affiliation: Departamento de Medicina Interna, Hospital de Especialidades, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Distrito Federal. olgavera62@yahoo.com.mx.
authors.forename: Olga Lidia
authors.initials: OL
authors.lastname: Vera-Lastra
authors.forename: Arturo
authors.initials: A
authors.lastname: Olvera-Acevedo
authors.forename: Claudia
authors.initials: C
authors.lastname: Hernández
authors.forename: Gabriela
authors.initials: G
authors.lastname: Medina
authors.forename: Ana Laura
authors.initials: AL
authors.lastname: Carrillo-González
authors.forename: Ulises
authors.initials: U
authors.lastname: Ángeles-Garay
authors.forename: Ana Lilia
authors.initials: AL
authors.lastname: Peralta-Amaro
authors.forename: Luis
authors.initials: L
authors.lastname: Jara
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D059168:Carotid Intima-Media Thickness; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D000069438:Ezetimibe / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D008875:Middle Aged; D017035:Pravastatin / Q000627:therapeutic use*; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000069438:Ezetimibe; D017035:Pravastatin
keywords: Atherosclerosis; Ezetimibe; Intima media thickness; Pravastatin; Systemic lupus erythematosus